Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Summary

Zealand Pharma will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:20 p.m. ET. This event will feature a fireside chat and will be broadcast live via a webcast available on the company's website. Zealand Pharma is a biotechnology firm focused on developing peptide-based medicines, with over 10 drug candidates in clinical development. The company has collaborations with Boehringer Ingelheim and AstraZeneca to enhance patient access to its investigational agents.

Positive

• Participation in a prominent healthcare conference may enhance visibility and credibility.
• Collaborations with Boehringer Ingelheim and AstraZeneca could lead to expanded market opportunities.

Negative

• None.

Press release – No. 4/ 2022

Zealand Pharma to Participate in Morgan Stanley 20^th Annual Global Healthcare Conference

Copenhagen, DK and Boston, MA, September 7, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in a fireside chat at the Morgan Stanley 20^th Annual Global Healthcare Conference.

Morgan Stanley 20^th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Presentation: 12:20 p.m. ET / 6:20 p.m. CET

A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com

FAQ

When is Zealand Pharma participating in the Morgan Stanley Healthcare Conference?

Zealand Pharma will participate on September 14, 2022, at 12:20 p.m. ET.

Where can I watch the Zealand Pharma conference presentation?

The presentation can be watched live on Zealand Pharma's 'Events & Presentations' page on their website.

What is the focus of Zealand Pharma's drug development?

Zealand Pharma focuses on the discovery and development of innovative peptide-based medicines.

How many drug candidates has Zealand Pharma advanced into clinical development?

Zealand Pharma has advanced more than 10 drug candidates into clinical development.

Who are the collaboration partners for Zealand Pharma?

Zealand Pharma collaborates with Boehringer Ingelheim and AstraZeneca.